The company submitted data showing A400's efficacy in patients with advanced RET fusion-positive NSCLC in the first- or later-line treatment.
The firm's lead candidate, EN-374 for X-linked chronic granulomatous disease, is being evaluated in a Phase I/II trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback